Peptides for Metabolic Syndrome

About 40% of American adults meet the criteria for metabolic syndrome — that cluster of overlapping conditions (belly fat, high blood sugar, high blood pressure, abnormal cholesterol, and elevated triglycerides) that dramatically raises the risk of heart disease, type 2 diabetes, and stroke. Standard treatment involves lifestyle changes, statins, blood pressure medications, and sometimes diabetes drugs. These work. But they treat each component separately, and many patients still progress.

Peptide research is opening a different angle. Several peptides — from FDA-approved GLP-1 receptor agonists to experimental mitochondrial peptides — target the underlying biology that connects all five metabolic syndrome components. Some work through insulin signaling. Others reduce the chronic inflammation that drives the whole syndrome forward. A few address visceral fat specifically, the metabolic engine behind the condition.

This guide covers the research behind each peptide, what it does and doesn't prove, and where the science stands right now.

What Is Metabolic Syndrome?
Why Peptides Matter for Metabolic Syndrome
Semaglutide: The GLP-1 Agonist Reshaping Treatment
Tirzepatide: Dual Receptor Targeting
MOTS-c: The Mitochondrial Exercise Mimetic
BPC-157: Anti-Inflammatory and Metabolic Effects
CJC-1295 and Ipamorelin: Growth Hormone Secretagogues
AOD-9604: The Growth Hormone Fragment
Emerging Peptides in Metabolic Syndrome Research
Peptide Comparison Table
What the Research Doesn't Tell Us Yet
Frequently Asked Questions
The Bottom Line
References

What Is Metabolic Syndrome?

Metabolic syndrome isn't a single disease. It's a diagnostic label for a cluster of interrelated risk factors that tend to show up together. Under the widely used harmonized criteria (AHA/NHLBI), you have metabolic syndrome if you meet three or more of these five conditions [1]:

Elevated waist circumference — greater than 40 inches in men, 35 inches in women
High triglycerides — 150 mg/dL or above
Low HDL cholesterol — below 40 mg/dL in men, below 50 mg/dL in women
Elevated blood pressure — 130/85 mmHg or higher
Elevated fasting glucose — 100 mg/dL or higher

Each of these is a health risk on its own. Together, they multiply the danger. People with metabolic syndrome face a five-fold greater risk of developing type 2 diabetes and roughly double the risk of cardiovascular disease over the next 5 to 10 years [1].

The connecting thread is insulin resistance. When your cells stop responding properly to insulin, glucose builds up in the blood. The pancreas pumps out more insulin to compensate. That excess insulin promotes fat storage — especially visceral fat around the organs — and drives up triglycerides. Visceral fat, in turn, releases inflammatory cytokines (TNF-alpha, IL-6) that worsen insulin resistance, creating a cycle that pulls blood pressure, lipids, and blood sugar in the wrong direction simultaneously [2].

Globally, metabolic syndrome prevalence ranges from 14% to 39% depending on the criteria used and the population studied. In the United States, roughly 39.8% of adults qualify — and prevalence climbs above 56% in those over 60 [3].

Why Peptides Matter for Metabolic Syndrome

Conventional medications address metabolic syndrome one component at a time: a statin for cholesterol, metformin for blood sugar, an ACE inhibitor for blood pressure. That approach is necessary but incomplete, because metabolic syndrome isn't five separate problems. It's one interconnected metabolic failure.

Peptides are interesting here because several of them act on the shared biology — insulin signaling, chronic inflammation, visceral fat accumulation, mitochondrial dysfunction — that links all five components. A single peptide like semaglutide can simultaneously lower blood sugar, reduce body weight, improve lipid profiles, and bring down blood pressure. That's not because it does five different things. It's because it corrects a central metabolic problem (appetite dysregulation and insulin resistance), and the downstream components improve as a result.

Some peptides are FDA-approved with strong clinical trial backing. Others are still in animal studies. The evidence levels vary widely, and this guide will be clear about which is which.

Semaglutide: The GLP-1 Agonist Reshaping Treatment

Semaglutide is the peptide that's done the most to reshape metabolic syndrome treatment in real clinical practice. It's a GLP-1 receptor agonist — a synthetic version of the gut hormone glucagon-like peptide-1 — approved for type 2 diabetes (Ozempic) and obesity (Wegovy).

How It Addresses Metabolic Syndrome

GLP-1 receptor agonists work through multiple overlapping mechanisms. They increase insulin secretion in a glucose-dependent manner (meaning they stimulate insulin only when blood sugar is actually high), suppress glucagon release, slow gastric emptying, and reduce appetite through central nervous system signaling [4].

What makes semaglutide relevant for metabolic syndrome — rather than just diabetes — is that these effects cascade across all five diagnostic criteria:

Blood sugar. In the SUSTAIN clinical trial program, semaglutide reduced HbA1c by 1.5% to 1.8% compared to placebo, with some patients achieving reductions of over 2% [4].

Body weight. The STEP trials demonstrated average weight loss of 14.9% with semaglutide 2.4 mg weekly over 68 weeks — a magnitude previously only seen with bariatric surgery [5].

Blood pressure. In the SELECT trial, semaglutide reduced systolic blood pressure by 3.5 to 5 mmHg. That reduction appears driven partly by weight loss and partly by direct vascular effects [6].

Lipids. Semaglutide consistently lowers triglycerides and LDL cholesterol while modestly improving HDL levels across trials [4].

Waist circumference. Weight loss with semaglutide is disproportionately from visceral fat — the metabolically active abdominal fat that defines central obesity in metabolic syndrome [5].

Case-Level Evidence

A 2025 case report in Cureus described a 44-year-old man with poorly controlled type 2 diabetes, dyslipidemia, and hypertension — classic metabolic syndrome — who switched from sitagliptin to semaglutide. Within six months, his HbA1c dropped from 9.6% to 7.1%, LDL cholesterol fell from 194 mg/dL to 116 mg/dL, liver enzymes normalized, and renal function remained stable [7].

Cardiovascular Risk Reduction

The SELECT trial enrolled over 17,600 patients with obesity and established cardiovascular disease (but without diabetes) and showed a 20% reduction in major adverse cardiovascular events (MACE) with semaglutide compared to placebo [6]. This was the first trial to demonstrate that a weight-loss medication could reduce heart attacks and strokes in non-diabetic patients — a landmark result for the metabolic syndrome population.

Tirzepatide: Dual Receptor Targeting

Tirzepatide adds a second mechanism on top of what semaglutide does. It activates both the GLP-1 receptor and the GIP (glucose-dependent insulinotropic polypeptide) receptor. This dual action has produced results that exceed even semaglutide in some head-to-head comparisons.

Clinical Results Across Metabolic Syndrome Components

A post hoc analysis of the SURPASS clinical trial program specifically assessed tirzepatide's impact on metabolic syndrome prevalence. The results were striking [8]:

Component	Change with Tirzepatide (15 mg)
HbA1c reduction	Up to 2.6%
Body weight loss	Up to 13.9%
Triglyceride reduction	Significant, dose-dependent
HDL cholesterol	Increased
Systolic blood pressure	Decreased by 4.7–5.2 mmHg
LDL cholesterol	Decreased
Liver fat	Reduced by 8.09% (SURPASS-3 sub-trial)

The proportion of patients who still met criteria for metabolic syndrome decreased significantly during treatment — and the reductions hadn't plateaued by week 40–52, suggesting longer treatment produces even greater benefit [8].

Long-Term Data

The three-year SURMOUNT-1 extension showed that participants with prediabetes and obesity maintained approximately 20% body weight reduction on tirzepatide 15 mg, with sustained improvements in waist circumference, blood pressure, and lipid levels [9]. A post hoc analysis using a validated risk calculator showed significant reductions in predicted 10-year atherosclerotic cardiovascular disease (ASCVD) risk [9].

What GIP Adds

The GIP receptor component appears to drive additional benefits beyond GLP-1 alone. In healthy individuals, the incretin effect (the boost in insulin secretion you get from eating versus intravenous glucose) accounts for 50–70% of the postprandial insulin response. In people with type 2 diabetes, this drops to 20–30% [10]. Tirzepatide's dual action works to restore this impaired incretin response more completely.

GIP and GLP-1 also have complementary effects on lipid metabolism. GLP-1 indirectly promotes lipolysis, while GIP influences lipogenesis — and the combination appears to remodel adipose tissue function in ways that neither does alone [10].

MOTS-c: The Mitochondrial Exercise Mimetic

MOTS-c is a 16-amino-acid peptide encoded within the mitochondrial genome — one of the first mitochondrial-derived peptides ever identified. Its primary target is skeletal muscle, and its mechanism of action reads almost like a molecular description of exercise.

Mechanism of Action

MOTS-c inhibits the folate cycle and de novo purine biosynthesis, which leads to activation of AMPK (AMP-activated protein kinase) — the same energy-sensing pathway that exercise turns on [11]. AMPK activation triggers a cascade of metabolic improvements:

Increased glucose uptake in muscle (through GLUT4 translocation)
Improved insulin sensitivity
Increased fat oxidation
Reduced hepatic glucose output

Think of AMPK as the body's low-fuel warning system. When it's activated, cells shift from energy storage mode to energy burning mode. In people with metabolic syndrome, this switch is often stuck in the wrong position. MOTS-c pushes it back.

Preclinical Evidence

In mouse studies, MOTS-c treatment prevented both age-dependent and high-fat-diet-induced insulin resistance. It also prevented diet-induced obesity. When administered to obese mice already showing metabolic dysfunction, it improved glucose tolerance and reduced fat mass [11].

A 2025 study in Experimental & Molecular Medicine showed that MOTS-c levels decline with aging in pancreatic islet cells. Treating aged mouse pancreatic islets with MOTS-c reduced islet cell senescence and improved glucose intolerance in diabetic models [12]. Another 2025 study demonstrated that MOTS-c restores mitochondrial respiration in the type 2 diabetic heart — a finding with direct implications for the cardiovascular component of metabolic syndrome [13].

Human Data

Circulating MOTS-c levels are measurably lower in people with type 2 diabetes, gestational diabetes, coronary endothelial dysfunction, and in obese children and adolescents compared to healthy controls [14]. That correlation doesn't prove causation, but it fits the pattern of a peptide whose decline contributes to metabolic deterioration.

MOTS-c is now in early-phase human trials examining its effects on frailty, insulin resistance, and physical performance. However, delivery challenges remain — the peptide has a short half-life and low bioavailability, which has slowed clinical development [14].

The next-generation analog CB411, engineered for a longer half-life and greater potency, is currently in preclinical studies for NASH and obesity [14].

BPC-157: Anti-Inflammatory and Metabolic Effects

BPC-157 is a 15-amino-acid peptide isolated from human gastric juice. It's best known for wound healing and gut repair, but animal studies point to direct metabolic effects that are relevant to metabolic syndrome.

What the Animal Studies Show

In animal models, BPC-157 has been shown to:

Decrease glucose levels and increase insulin sensitivity — In rat models of insulin resistance, BPC-157 treatment improved glycemic control and reduced markers of insulin resistance [15].
Protect against insulin overdose — Rats treated with BPC-157 before insulin overdose showed higher blood glucose levels (glycogen was still present in hepatocytes), less liver damage, reduced fatty liver, lower ALT, AST, and amylase values, and avoided the fatal outcomes seen in untreated animals [16].
Reduce fatty liver — BPC-157 decreased hepatic steatosis in multiple animal models, which matters because non-alcoholic fatty liver disease (NAFLD) frequently accompanies metabolic syndrome [15].
Modulate systemic inflammation — The peptide regulates production of inflammatory cytokines and interacts with the nitric oxide system, both of which are central to the chronic low-grade inflammation that drives metabolic syndrome [15].

The Gut-Metabolism Connection

BPC-157 modulates the gut-brain axis and influences systemic cytokine production. Given the growing understanding of gut health's role in metabolic disease — from intestinal permeability ("leaky gut") contributing to systemic inflammation, to gut microbiome composition affecting insulin sensitivity — this gut-centric mechanism may be more relevant to metabolic syndrome than it first appears [15].

Limitations

The evidence base for BPC-157 in metabolic syndrome is entirely preclinical. There are no completed human clinical trials examining its effects on blood sugar, lipids, blood pressure, or body composition. The peptide was in Phase II clinical trials for inflammatory bowel disease, but metabolic endpoints haven't been formally studied in humans. BPC-157 is not FDA-approved for any indication.

CJC-1295 and Ipamorelin: Growth Hormone Secretagogues

CJC-1295 and ipamorelin are growth hormone secretagogues — they stimulate your pituitary gland to release more growth hormone (GH). They're often used together because they work through different receptors (GHRH receptor and ghrelin receptor, respectively) and the combination produces a 3-to-5-fold increase in GH release compared to either one alone.

Metabolic Rationale

The metabolic rationale is straightforward: growth hormone declines with age, and this decline correlates with increased visceral fat, decreased lean mass, worsening insulin sensitivity, and unfavorable lipid profiles — essentially, the progression toward metabolic syndrome.

In a clinical study, a single injection of CJC-1295 produced dose-dependent increases in plasma GH concentrations of 2- to 10-fold sustained for 6 or more days, and increases in IGF-1 of 1.5- to 3-fold for 9 to 11 days [17].

Growth hormone influences metabolic syndrome components through several mechanisms [18]:

Lipolysis — GH activates hormone-sensitive lipase, promoting fat breakdown, particularly in visceral depots
Protein synthesis — Through mTOR and PI3K/Akt pathways, supporting lean mass maintenance
Insulin sensitivity — IGF-1-mediated improvements in insulin signaling
Glucose uptake — Improved glucose utilization in skeletal muscle
Energy expenditure — Potential increases in basal metabolic rate

The GH-Insulin Paradox

Here's where it gets complicated. Growth hormone itself can cause insulin resistance in the short term. GH shifts fuel use from glucose to fat — good for body composition, potentially problematic for blood sugar control. In people who already have impaired glucose tolerance, increasing GH levels may temporarily worsen insulin sensitivity before the body composition improvements catch up [18].

This means that CJC-1295 and ipamorelin require careful monitoring in anyone with existing metabolic syndrome, especially those with prediabetes or diabetes. Dose adjustments may be necessary, and these peptides are not appropriate for everyone.

Evidence Level

CJC-1295 and ipamorelin are not FDA-approved. The clinical data comes primarily from small pharmacokinetic studies and short-term safety trials. No large clinical trials have specifically evaluated their effects on metabolic syndrome outcomes. Their metabolic relevance is inferred from growth hormone physiology rather than demonstrated in controlled metabolic syndrome trials.

AOD-9604: The Growth Hormone Fragment

AOD-9604 takes a targeted approach. It's a synthetic fragment of human growth hormone (amino acids 176–191) designed to isolate the fat-burning properties of GH while eliminating effects on IGF-1 and blood sugar.

What Makes It Different

Unlike full-length growth hormone, AOD-9604 specifically activates lipolysis in fat tissue through interaction with beta-3 adrenergic receptors. In obese mice, both GH and AOD-9604 increased the expression of beta-3 adrenergic receptor RNA — the major lipolytic receptor in fat cells — to levels comparable with lean mice [19].

The selectivity matters for metabolic syndrome. Full growth hormone raises blood sugar. AOD-9604, in the studies conducted so far, did not change IGF-1 levels, did not impair glucose homeostasis, and did not cause anabolic tissue growth — a safety profile that's more appropriate for a population already dealing with insulin resistance [19].

Clinical Data

Over 900 participants were studied across six randomized, double-blind, placebo-controlled trials. In a 12-week study, subjects receiving AOD-9604 (1 mg/day) lost an average of 2.6 kg compared to 0.8 kg with placebo. However, a larger 24-week trial of 536 subjects failed to show significant weight loss, and drug development was terminated in 2007 [20].

This is a peptide where the mechanism is sound but the clinical results were underwhelming at the doses and durations tested. It's unclear whether different dosing strategies might produce better results.

Emerging Peptides in Metabolic Syndrome Research

Several newer peptides and combination therapies are entering the metabolic syndrome research space:

Retatrutide (triple agonist). This peptide activates GLP-1, GIP, and glucagon receptors simultaneously. Phase 2 trial data showed mean weight loss of 24.2% after 48 weeks in people with obesity — approaching bariatric surgery levels. The glucagon receptor activation component adds energy expenditure and hepatic fat reduction on top of the appetite suppression from GLP-1 and GIP [21].

CagriSema (cagrilintide + semaglutide). This combination pairs a long-acting amylin analog with semaglutide. Amylin and GLP-1 both reduce appetite and slow gastric emptying, but through different neural pathways. The combination has achieved 22–24% weight loss in trials — suggesting the two mechanisms are genuinely additive [22].

PEPITEM. This peptide, discovered in Birmingham, UK, reduced pancreatic islet cell enlargement and white blood cell infiltration in visceral adipose tissue when administered to mice on a high-fat diet. Researchers have proposed it could benefit people with obesity-related insulin resistance and inflammatory conditions [23].

Catestatin (CST). A naturally occurring peptide that, in obese mice, improved glucose and insulin tolerance, reduced body weight, decreased liver inflammation, and lowered blood sugar to normal levels. It works by inhibiting monocyte-derived macrophage recruitment to the liver — directly targeting the inflammatory pathway that connects visceral obesity to insulin resistance [24].

Peptide Comparison Table

Peptide	Primary Mechanism	Blood Sugar	Body Weight	Lipids	Blood Pressure	Evidence Level
Semaglutide	GLP-1 receptor agonism	Strong reduction	15% average loss	Improves TG, LDL, HDL	Modest reduction	FDA-approved, large RCTs
Tirzepatide	GLP-1 + GIP dual agonism	Strongest reduction	Up to 20% loss	Broad improvement	4–5 mmHg SBP reduction	FDA-approved, large RCTs
MOTS-c	AMPK activation (exercise mimetic)	Improves in animals	Reduces obesity in mice	Not directly studied	Not directly studied	Preclinical + early human trials
BPC-157	Anti-inflammatory, NO system	Improves in animals	Indirect (via inflammation)	Not directly studied	Not directly studied	Preclinical only
CJC-1295 + Ipamorelin	GH secretion	Mixed (may worsen short-term)	Reduces visceral fat	May improve	Not directly studied	Small clinical PK studies
AOD-9604	Selective lipolysis	Neutral	Modest in trials	Not directly studied	Not directly studied	Phase II failed primary endpoint
Retatrutide	GLP-1 + GIP + glucagon triple agonism	Strong reduction	24% loss (Phase 2)	Likely improves	Likely improves	Phase 2 completed
CagriSema	Amylin + GLP-1	Strong reduction	22–24% loss	Likely improves	Likely improves	Phase 3 ongoing

What the Research Doesn't Tell Us Yet

The gap between what we know and what we need to know is still wide, even for FDA-approved options.

Long-term metabolic syndrome reversal. Semaglutide and tirzepatide clearly improve all five metabolic syndrome components during treatment. What happens after stopping? The STEP 1 extension trial showed significant weight regain and metabolic deterioration after semaglutide discontinuation [5]. This raises the question: are these treatments cures or maintenance therapies?

Head-to-head comparisons. Direct comparisons between different peptide approaches for metabolic syndrome are almost nonexistent. We don't know whether tirzepatide's dual action produces meaningfully better metabolic syndrome outcomes than semaglutide alone, or whether adding MOTS-c or BPC-157 to standard therapy offers any additional benefit.

Combination protocols. The peptide stacking guide concept — using multiple peptides together — is common in clinical practice but rarely studied in controlled trials. Whether combining a GLP-1 agonist with a growth hormone secretagogue or a mitochondrial peptide produces synergistic metabolic benefits, additive effects, or unexpected interactions is unknown.

Population-specific responses. Metabolic syndrome looks different in a 35-year-old woman with PCOS than in a 65-year-old man with coronary artery disease. Peptide responses likely vary by age, sex, genetics, and metabolic phenotype. Biomarker-guided peptide selection is a promising concept without current evidence to support it.

Frequently Asked Questions

What is the most effective peptide for metabolic syndrome?

Based on current evidence, tirzepatide has the strongest published data for improving all five components of metabolic syndrome simultaneously. Semaglutide is close behind, with additional cardiovascular outcome data from the SELECT trial. Both are FDA-approved. Other peptides like MOTS-c and BPC-157 show promise in preclinical research but lack the human trial data to make definitive claims.

Can peptides reverse metabolic syndrome completely?

In the SURPASS trials, a significant proportion of patients treated with tirzepatide no longer met the diagnostic criteria for metabolic syndrome by week 40–52 [8]. However, stopping treatment often leads to regression. The current evidence suggests peptides can control metabolic syndrome effectively but may need to be continued long-term for sustained benefit.

Are peptides for metabolic syndrome safe?

FDA-approved GLP-1 agonists (semaglutide, tirzepatide, liraglutide) have extensive safety data from clinical trials involving tens of thousands of patients. The most common side effects are gastrointestinal — nausea, vomiting, diarrhea — typically at treatment initiation and dose escalation. Experimental peptides (MOTS-c, BPC-157, CJC-1295) have limited human safety data and are not FDA-approved.

How do peptides compare to metformin for metabolic syndrome?

Metformin primarily addresses the glucose component of metabolic syndrome and has modest effects on weight (1–3 kg loss). GLP-1 receptor agonists produce substantially greater weight loss (10–20%), stronger HbA1c reductions, and documented improvements in blood pressure, lipids, and cardiovascular outcomes. However, metformin remains a first-line option due to its long track record, oral dosing, low cost, and favorable safety profile.

Do I need a prescription for peptides that treat metabolic syndrome?

Semaglutide, tirzepatide, and liraglutide require prescriptions and are available through standard pharmacies. Other peptides discussed in this guide (BPC-157, CJC-1295, ipamorelin, MOTS-c, AOD-9604) are not FDA-approved for metabolic syndrome or any other indication. Their availability varies by jurisdiction and is subject to evolving regulatory oversight. For guidance on the current status of peptide therapies for metabolic conditions, consult the peptides for diabetes management and peptides for obesity guides.

The Bottom Line

Metabolic syndrome is a system-level problem, and the most effective peptide approaches work at the system level. Semaglutide and tirzepatide have the strongest evidence — not just for individual components, but for shifting the entire metabolic profile in a favorable direction. The cardiovascular outcome data from SELECT adds real clinical weight to this beyond just lab numbers on a page.

Behind them, a second tier of peptides addresses the underlying biology through different angles. MOTS-c mimics the metabolic effects of exercise at the molecular level. BPC-157 targets the gut-inflammation axis. Growth hormone secretagogues address body composition. Each offers a distinct mechanism, but each also carries a proportionally thinner evidence base.

If you have metabolic syndrome, the conversation with your doctor should start with what's proven — lifestyle changes, established medications, and now GLP-1-based therapies with strong outcome data. The experimental peptides are worth understanding, not as replacements, but as indicators of where metabolic medicine is headed. Also see related guides on peptides for insulin resistance, best peptides for fat loss, and best peptides for cardiovascular health.

References

Alberti, K.G. et al. "Harmonizing the metabolic syndrome: a joint interim statement of the IDF, NHLBI, AHA, WHF, IAS, and IASO." Circulation, 120(16), 1640–1645 (2009). PubMed
Guarino, G. et al. "Metabolic syndrome: epidemiology, mechanisms, and current therapeutic approaches." Frontiers in Nutrition (2025). Frontiers
Hirode, G. & Wong, R.J. "Trends in the prevalence of metabolic syndrome in the United States, 2011–2016." JAMA, 323(24), 2526–2528 (2020). StatPearls
Drucker, D.J. "GLP-1 receptor agonists: mechanisms and advances in therapy." Signal Transduction and Targeted Therapy (2024). Nature
Wilding, J.P.H. et al. "Once-weekly semaglutide in adults with overweight or obesity." New England Journal of Medicine, 384(11), 989–1002 (2021). NEJM
Lincoff, A.M. et al. "Semaglutide and cardiovascular outcomes in obesity without diabetes." New England Journal of Medicine, 389(24), 2221–2232 (2023). NEJM
"The impact of semaglutide on metabolic syndrome: a case report." Cureus (2025). PMC
Sattar, N. et al. "Reduction of prevalence of patients meeting the criteria for metabolic syndrome with tirzepatide: a post hoc analysis from the SURPASS Clinical Trial Program." Cardiovascular Diabetology, 23, 52 (2024). Springer
Sattar, N. et al. "Tirzepatide and cardiometabolic parameters in obesity: summary of current evidence." Diabetes, Obesity and Metabolism (2025). PMC
Baggio, L.L. & Drucker, D.J. "Glucagon-like peptide-1 receptor co-agonists for treating metabolic disease." Molecular Metabolism, 46, 101090 (2021). ScienceDirect
Lee, C. et al. "The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance." Cell Metabolism, 21(3), 443–454 (2015). Cell
Kim, S.J. et al. "Mitochondrial-encoded peptide MOTS-c prevents pancreatic islet cell senescence to delay diabetes." Experimental & Molecular Medicine (2025). Nature
"Mitochondria-derived peptide MOTS-c restores mitochondrial respiration in type 2 diabetic heart." Frontiers in Physiology (2025). Frontiers
Merry, T.L. et al. "MOTS-c: a promising mitochondrial-derived peptide for therapeutic exploitation." PMC (2023). PMC
Seiwerth, S. et al. "Multifunctionality and possible medical application of the BPC 157 peptide — literature and patent review." Pharmaceuticals, 18(2), 185 (2025). MDPI
Ilic, S. et al. "Over-dose insulin and stable gastric pentadecapeptide BPC 157." Journal of Physiology and Pharmacology, 60 Suppl 7, 107–114 (2009). PubMed
Teichman, S.L. et al. "Prolonged stimulation of growth hormone and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults." JCEM, 91(3), 799–805 (2006). PubMed
Frago, L.M. & Chowen, J.A. "Growth hormone and metabolic regulation." Endocrine Reviews (2024). [Various clinical references on GH and metabolic effects]
Heffernan, M.A. et al. "The effects of human GH and its lipolytic fragment (AOD9604) on lipid metabolism following chronic treatment in obese mice and beta(3)-AR knock-out mice." Endocrinology, 142(12), 5182–5189 (2001). PubMed
Moré, M.I. et al. "Safety and metabolism of AOD9604, a novel nutraceutical ingredient for improved metabolic health." Journal of Endocrinology and Metabolism (2023). JofEM
Jastreboff, A.M. et al. "Triple–hormone-receptor agonist retatrutide for obesity — a phase 2 trial." New England Journal of Medicine, 389(6), 514–526 (2023). NEJM
"GLP-1R and amylin agonism in metabolic disease: complementary mechanisms and future opportunities." PMC (2012). PMC
"Obesity, diabetes: natural peptide holds therapeutic promise." Medical News Today (2024). MNT
"Peptide improves glucose and insulin sensitivity, lowers weight in mice." ScienceDaily (2018). ScienceDaily

Table of Contents